RIM
RVNC

RS Investment Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

RS Investment Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-421,566
Closed -$8.15M – 397
2014
Q3 		$8.15M Buy
421,566
+72,000
+21% +$1.88M 0.08% 252
2014
Q2 		$11.9M Buy
349,566
+33,566
+11% +$1.05M 0.1% 220
2014
Q1 		$9.95M Buy
+316,000
New +$9.87M 0.06% 229

Other funds holding RVNC

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
NHG
NQ HCIF GP Raleigh, North Carolina $50.2M AUM 45.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

RS Investment Management's RVNC Position: Q4 2014 in Review

RS Investment Management sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2014, closing a stake of 421,566 shares — an estimated $8.15M sold.

RS Investment Management first reported a position in RVNC in Q1 2014 and held it in 3 quarters. The position peaked at $11.9M in Q2 2014. 69 funds tracked by Wall St. Rank hold RVNC as of Q4 2014.

  • RS Investment Management reported no remaining Revance Therapeutics, Inc. position as of Q4 2014 after selling out during the quarter.
  • RS Investment Management sold 421,566 Revance Therapeutics, Inc. shares in Q4 2014, an estimated $8.15M.
  • RS Investment Management first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 3 quarters.
  • RS Investment Management's Revance Therapeutics, Inc. position peaked at $11.9M in Q2 2014.
  • 69 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2014.

Based on RS Investment Management's 13F filing for Q4 2014, filed 12 Feb 2015.